WATCHMAN Growth and Trial Wins Boost Structural Heart Prospects, But Near-Term Headwinds Persist

What happened

Boston Scientific's WATCHMAN device posted 19% growth and positive trial results, supporting the company's plan to expand the addressable patient population from 5 million to 20 million worldwide. However, this positive development comes against a backdrop of near-term headwinds highlighted in the latest DeepValue Master Report, including worse-than-expected electrophysiology (EP) share loss and deceleration in Watchman procedure volumes in early 2026. The pending $14.5B Penumbra acquisition also introduces significant financing risk, with the company funding the deal through $11B in cash and new debt while simultaneously executing a $2B accelerated share repurchase. Management's credibility hinges on whether EP competition stabilizes and Watchman volumes recover in the second half of 2026, as current guidance implies. While the WATCHMAN news supports the bull-case scenario of procedure growth re-acceleration, it does not yet resolve the operational issues that keep the stock's risk-reward balanced at current levels.

Implication

Investors should monitor Q2 2026 earnings for evidence that EP share loss has stabilized and Watchman procedures have inflected upward. The WATCHMAN trial wins are encouraging for the 2027+ outlook, but without near-term operational improvement, the stock lacks a catalyst given elevated leverage from the Penumbra deal. A more attractive entry point may emerge if the stock dips toward $52, as per the DeepValue report's attractive entry price. Until then, the risk-reward is balanced, with the bull case dependent on evidence-to-practice translation of these trial results.

Thesis delta

The WATCHMAN news reinforces the bull scenario but does not alter the core thesis that near-term returns depend on EP share stabilization and Watchman volume recovery ahead of the Penumbra deal close. The 19% growth and expanded addressable market provide a long-term positive, but the immediate headwinds remain, maintaining the WAIT rating.